In conclusion, the study suggests that combining chemotherapy with angiogenesis inhibitors may offer a superior survival benefit in the first-line setting for HER2-altered NSCLC while indicating that immune-based combination therapy may not surpass the efficacy of chemotherapy alone. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.